[go: up one dir, main page]

ATE501255T1 - 84p2a9: prostata- und hodenspezifisches protein, das sehr stark bei prostatakrebs vorkommt - Google Patents

84p2a9: prostata- und hodenspezifisches protein, das sehr stark bei prostatakrebs vorkommt

Info

Publication number
ATE501255T1
ATE501255T1 AT08154530T AT08154530T ATE501255T1 AT E501255 T1 ATE501255 T1 AT E501255T1 AT 08154530 T AT08154530 T AT 08154530T AT 08154530 T AT08154530 T AT 08154530T AT E501255 T1 ATE501255 T1 AT E501255T1
Authority
AT
Austria
Prior art keywords
prostate
testis
specific protein
testis specific
fragment
Prior art date
Application number
AT08154530T
Other languages
English (en)
Inventor
Aya Jakobovits
Daniel E H Afar
Pia M Challita-Eid
Elana Levin
Steve Chappell Mitchell
Rene S Hubert
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc filed Critical Agensys Inc
Application granted granted Critical
Publication of ATE501255T1 publication Critical patent/ATE501255T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT08154530T 2000-01-26 2001-01-26 84p2a9: prostata- und hodenspezifisches protein, das sehr stark bei prostatakrebs vorkommt ATE501255T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17856000P 2000-01-26 2000-01-26

Publications (1)

Publication Number Publication Date
ATE501255T1 true ATE501255T1 (de) 2011-03-15

Family

ID=22653018

Family Applications (2)

Application Number Title Priority Date Filing Date
AT08154530T ATE501255T1 (de) 2000-01-26 2001-01-26 84p2a9: prostata- und hodenspezifisches protein, das sehr stark bei prostatakrebs vorkommt
AT01910358T ATE392474T1 (de) 2000-01-26 2001-01-26 84p2a9: prostata- und testis-spezifisches protein das hohe expression in prostatakrebs aufweist

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01910358T ATE392474T1 (de) 2000-01-26 2001-01-26 84p2a9: prostata- und testis-spezifisches protein das hohe expression in prostatakrebs aufweist

Country Status (12)

Country Link
US (3) US7510855B2 (de)
EP (2) EP1967586B1 (de)
JP (2) JP3946044B2 (de)
AT (2) ATE501255T1 (de)
AU (2) AU3797301A (de)
CA (1) CA2398064C (de)
CY (1) CY1111522T1 (de)
DE (2) DE60144204D1 (de)
DK (1) DK1967586T3 (de)
ES (2) ES2360155T3 (de)
IL (2) IL150873A0 (de)
WO (1) WO2001055391A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE501255T1 (de) * 2000-01-26 2011-03-15 Agensys Inc 84p2a9: prostata- und hodenspezifisches protein, das sehr stark bei prostatakrebs vorkommt
DK1994155T4 (da) * 2006-02-13 2022-07-25 Daiichi Sankyo Co Ltd Polynukleotid- og polypeptidsekvenser involveret i fremgangsmåden med knogleremodellering
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
IN2014KN02933A (de) 2012-07-19 2015-05-08 Alethia Biotherapeutics Inc
US20150231199A1 (en) * 2012-09-07 2015-08-20 Agency For Science, Technology And Research Peptides and their uses

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
PL196260B1 (pl) 1997-02-25 2007-12-31 Corixa Corp Polipeptyd, cząsteczka DNA, komórka gospodarza, białko fuzyjne, kompozycje farmaceutyczne i szczepionki do leczenia raka prostaty
WO1998045435A2 (en) 1997-04-10 1998-10-15 Genetics Institute, Inc. SECRETED EXPRESSED SEQUENCE TAGS (sESTs)
WO1999038972A2 (en) 1998-01-28 1999-08-05 Chiron Corporation Human genes and gene expression products ii
US6013450A (en) 1998-02-20 2000-01-11 Incyte Pharmaceuticals, Inc. CAF1-related protein
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
EP1074617A3 (de) * 1999-07-29 2004-04-21 Research Association for Biotechnology Primers für Synthese von ganzen-Länge cDNS und deren Anwendung
WO2001051628A2 (en) 2000-01-14 2001-07-19 Millennium Pharmaceuticals, Inc. Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
ATE501255T1 (de) * 2000-01-26 2011-03-15 Agensys Inc 84p2a9: prostata- und hodenspezifisches protein, das sehr stark bei prostatakrebs vorkommt
AU2001241408A1 (en) 2000-01-31 2001-08-07 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
WO2001077289A2 (en) 2000-04-06 2001-10-18 Genetics Institute, Llc. Polynucleotides encoding novel secreted proteins
CN1328147A (zh) 2000-06-12 2001-12-26 上海博德基因开发有限公司 一种新的多肽——人磷脂酶49.06和编码这种多肽的多核苷酸
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
US20030165843A1 (en) 2000-07-28 2003-09-04 Avi Shoshan Oligonucleotide library for detecting RNA transcripts and splice variants that populate a transcriptome
EP1346040A2 (de) 2000-09-11 2003-09-24 Nuvelo, Inc. Nukleinsäuren und polypeptide
EP1325120A4 (de) 2000-10-12 2005-05-25 Nuvelo Inc Neue nukleinsäuren und polypeptide
WO2002059271A2 (en) 2001-01-25 2002-08-01 Gene Logic, Inc. Gene expression profiles in breast tissue

Also Published As

Publication number Publication date
IL150873A (en) 2010-02-17
EP1250434A2 (de) 2002-10-23
EP1250434B1 (de) 2008-04-16
EP1967586B1 (de) 2011-03-09
US8013126B2 (en) 2011-09-06
ES2360155T3 (es) 2011-06-01
JP5501550B2 (ja) 2014-05-21
AU3797301A (en) 2001-08-07
US20040126862A1 (en) 2004-07-01
DE60144204D1 (de) 2011-04-21
DK1967586T3 (da) 2011-06-20
DE60133627T2 (de) 2009-07-30
US7510855B2 (en) 2009-03-31
JP2006325595A (ja) 2006-12-07
JP2003520605A (ja) 2003-07-08
US7582448B2 (en) 2009-09-01
CA2398064A1 (en) 2001-08-02
IL150873A0 (en) 2003-02-12
JP3946044B2 (ja) 2007-07-18
CA2398064C (en) 2012-12-18
CY1111522T1 (el) 2015-08-05
WO2001055391A3 (en) 2002-02-21
US20090170191A1 (en) 2009-07-02
WO2001055391A2 (en) 2001-08-02
ATE392474T1 (de) 2008-05-15
US20070054363A1 (en) 2007-03-08
AU2001237973B2 (en) 2006-09-07
DE60133627D1 (de) 2008-05-29
EP1967586A1 (de) 2008-09-10
ES2304126T3 (es) 2008-09-16

Similar Documents

Publication Publication Date Title
ATE420175T1 (de) C-typ lektin transmembranantigen, das in menschlichen prostatkrebs exprimiert wird, und deren verwendungen
NO20004631D0 (no) Forbindelser og fremgangsmÕter for terapi og diagnose av lungekreft
IL145731A0 (en) A polypetide containing an immunogenic portion of a breast tumor protein and pharmaceutical compositions containing the same
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
BR0113491A (pt) Polinucleotìdeo e polipeptìdeo isolados, vetor de expressão, célula hospedeira, proteìna de fusão, métodos para estimular e/ou expandir células t especìficas para uma protéina de tumor, para estimular uma resposta imune em um paciente, para o tratamento de um câncer em um paciente e para inibir o desenvolvimento de um câncer em um paciente, população de célula t isolada, composição, e, uso de um componente.
WO2005062972A3 (en) Treatment of cancer with novel anti-il 13 monoclonal antibodies
WO1999033869A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
TR200001646T2 (tr) Bir salgılanmış meme kanseri proteini olan mamaglobin.
WO1998045328A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
EP1706423B8 (de) Therapeutische und diagnostische anti-hsp 70-antikörper
WO2001071357A3 (en) Diagnosis and treatment of breast cancer
CY1111522T1 (el) 84p2a9: ειδικη σε προστατη και ορχεις πρωτεϊνη που εκφραζεται σε υψηλο βαθμο στον προστατικο καρκινο
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
DE60130541D1 (de) Gewebe-spezifische protein 103p2d6, hochexprimiert in verschiedene krebsarten
EP1351967A4 (de) Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs
DK1313850T3 (da) Nucleinsyre og tilsvarende protein med navnet 85PB3 anvendelige til behandling og påvisning af cancer
WO2001096391A3 (en) 55p4h4: gene expressed in various cancers
WO2003020954A3 (en) 205p1b5 in treatment and detection of cancer
WO2001079557A3 (en) Gtp-binding protein useful in treatment and detection of cancer
WO2001059110A3 (en) 34p3d7: a tissue specific protein highly expressed in prostate cancer
WO2001059115A3 (en) 83p5g4: a tissue specific protein highly expressed in prostate cancer
WO2003042700A3 (en) Breast cancer associated polypeptide
WO2002088380A3 (en) Immunogenic tumor antigens: nucleic acids and polypeptides encoding the same and methods of use thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1967586

Country of ref document: EP